ALLI INTL ED LE (01563) released its annual performance report, with the owner's share of net profit for the year reaching 44.862 million yuan, a year-on-year increase of 70.82%.
Global Education Leasing (01563) released its annual performance for the year ending March 31, 2026, with revenue of approximately 754 million yuan, an increase of 2.57% compared to the previous year. The company's owners' share of the annual net profit was 448.62 million yuan, a year-on-year increase of 70.82%. Basic earnings per share were 0.0265 yuan.
ALLI INTL ED LE (01563) announced its financial performance for the year ending on March 31, 2026, with revenue of approximately 754 million yuan, a year-on-year increase of 2.57%; the company's attributable net profit for the year was 44.862 million yuan, a year-on-year increase of 70.82%; basic earnings per share were 0.0265 yuan.
According to the announcement, the group's revenue mainly comes from higher education and financing and operating leasing businesses. Revenue generated by the group's higher education business is primarily from tuition and accommodation fees, all of which are generated in China. Revenue from the leasing business is derived from interest receivable, as well as services related to sale and leaseback, direct financing leases, and ship leasing.
Related Articles

Brokerage morning meeting highlights | Brand focus on high-performance certainty targets creating attention on marginal improvement opportunities

C HEALTH GP(08225): It is recommended to adopt the new equity purchase plan.

HUTCHMED (00013) will release key phase II trial data on fruquintinib for the treatment of intrahepatic cholangiocarcinoma at the 2026 European Society for Medical Oncology Congress on Gastrointestinal Oncology.
Brokerage morning meeting highlights | Brand focus on high-performance certainty targets creating attention on marginal improvement opportunities

C HEALTH GP(08225): It is recommended to adopt the new equity purchase plan.

HUTCHMED (00013) will release key phase II trial data on fruquintinib for the treatment of intrahepatic cholangiocarcinoma at the 2026 European Society for Medical Oncology Congress on Gastrointestinal Oncology.

RECOMMEND





